Cutting edge: Chemotactic activity of soluble Fas ligand against phagocytes

Journal of Immunology

Volumn 161, Issue 9, 1998, Pages 4484-4488

  Seino, Ken Ichiro ^a,b   Iwabuchi, Kazuhisa ^a   Kayagaki, Nobuhiko ^a   Miyata, Ryukou ^a   Nagaoka, Isao ^a   Matsuzawa, Akio ^c   Fukao, Katashi ^b   Yagita, Hideo ^a,d   Okumura, Ko ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYL SULFOXIDE; FAS ANTIGEN; FAS LIGAND; FORMYLMETHIONYLLEUCYLPHENYLALANINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN M; INTERLEUKIN 8; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PHORBOL 13 ACETATE 12 MYRISTATE; RECOMBINANT PROTEIN; CHEMOTACTIC FACTOR; FASL PROTEIN, MOUSE; FASLG PROTEIN, HUMAN; HYBRID PROTEIN; MEMBRANE PROTEIN;

ANIMAL CELL; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL STRAIN HL 60; CONTROLLED STUDY; HUMAN; HUMAN CELL; MONOCYTE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; ANIMAL; APOPTOSIS; C3H MOUSE; CHEMISTRY; DRUG EFFECT; GENETICS; IMMUNOLOGY; LYMPHOPROLIFERATIVE DISEASE; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; MUTATION; NEUTROPHIL; PATHOLOGY; PROTEIN TERTIARY STRUCTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; APOPTOSIS; CHEMOTACTIC FACTORS; CHEMOTAXIS, LEUKOCYTE; FAS LIGAND PROTEIN; HL-60 CELLS; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C3H; MICE, INBRED MRL LPR; MUTATION; NEUTROPHILS; PHAGOCYTES; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS;

EID: 0032209454     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Nagata, S. 1997. Apoptosis by death factor. Cell 88:355.
2. Kayagaki, N., A. Kawasaki, T. Ebata, H. Ohmoto, S. Ikeda, S. Inoue, K. Yoshino, K. Okumura, and H. Yagita. 1995. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 182:1777.
3. Tanaka, M., T. Suda, T. Takahashi, and S. Nagata. 1995. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J. 14:1129.
4. Nagata, S., and P. Golstein. 1995. The Fas death factor. Science 267:1449.
5. Bellgrau, D., D. Gold, H. Selawry, J. Moore, A. Franzusoff, and R. C. Duke. 1995. A role for CD95 ligand in preventing graft rejection. Nature 377:630.
6. Griffith, T. S., T. Brunner, S. M. Fletcher, D. R. Green, and T. A. Ferguson. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270: 1189.
7. Hahne, M., D. Rismolde, M. Schroter, P. Romero, M. Screier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, et al. 1996. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363.
8. Strand, S., W. J. Hofmann, H. Hug, M. Muller, G. Otto, D. Strand, S. M. Mariani, W. Stremel, P. H. Krammer, and P. R. Galle. 1996. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells: a mechanism of immune evasion? Nature Med. 2:1361.
9. Lau, H. T., M. Yu, A. Fontana, and C. J. Stoeckert, Jr. 1996. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 273:109.
10. Seino, K., N. Kayagaki, K. Okumura, and H. Yagita. 1997. Antitumor effect of locally produced CD95 ligand. Nature Med. 3:165.
11. Allison, J., H. M. Georgiou, A. Strasser, and D. L. Vaux. 1997. Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration, but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci. USA 94:3943.
12. Kang, S.-M., D. B. Schneider, Z. Lin, D. Hanahan, D. A. Dichek, P. G. Strock, and S. Baekkeskov. 1997. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Med. 3:738.
13. Oyaizu, N., N. Kayagaki, H. Yagita, S. Pahwa, and Y. Ikawa. 1997. Requirement of cell-cell contact in the induction of Jurkat cell apoptosis: the membrane-anchhored but not soluble form of FasL can trigger anti-CD3-induced apoptosis in Jurkat T cells. Biochem. Biophys. Res. Commun. 238:670.
14. cg, that complements the gld gene in induction of lymphadenopathy in the mouse. J. Exp. Med. 171:519.
15. Bogen, S., J. Pak, M. Garifallou, X. Deng, and W. A. Muller. 1994. Monoclonal antibody to murine PECAM-1 (CD31) blocks acute inflammation in vivo. J. Exp. Med. 179:1059.
16. Iwabuchi, K., I. Nagaoka, A. Someya, and T. Yamashita. 1996. Type IV collagen-binding proteins of neutrophils: possible involvement of L-selectin in the neutrophil binding to type IV collagen. Blood 87:365.
17. Hickstein, D., A. Smith, W. Fisher, P. Beatty, B. Schwartz, J. Harlan, R. Root, and R. Locksley. 1987. Expression of leukocyte adherence-related glycoproteins during differentiation of HL-60 promyelocytic leukemia cells. J. Immunol. 138: 513.
18. Bohnsack, J., and J. Chang. 1994. Activation of β 1 integrin fibronectin receptors on HL60 cells after granulocytic differentiation. Blood 83:543.
19. Zigmond, S. H., and J. G. Hirsch. 1972. Effects of cytocalasin B on polymorphonuclear leukocyte locomotion, phagocytosis and glycolysis. Exp. Cell. Res. 73:383.
20. Tanaka, M., T. Itai, M. Adachi, and S. Nagata. 1998. Downregulation of Fas ligand by shedding. Nature Med. 4:31.
21. Suda, T., H. Hashimoto, M. Tanaka, T. Ochi, and S. Nagata. 1997. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med. 186:2045.
22. Schneider, P., N. Holler, J. L. Bodmer, M. Hahne, K. Frei, A. Fontana, and J. Tschopp. 1998. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187:1205.
23. Medema, J. P., C. Scaffidi, F. C. Kischkel, A. Shevchenko, M. Mann, P. H. Krammer, and M. Peter. 1997. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 16:2794.
24. Duan, H., and V. M. Dixit. 1997. RAIDD is a new "death" adaptor molecule. Nature 385:86.
25. Yang, X., R. Khorsravi-Far, H. Y. Chang, and D. Baltimore. 1997. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell 1067.
26. Rensing-Ehl, A., S. Hess, H. Ziegler-Heitbrock, G. Riethmuller, and H. Engelmann. 1995. Fas/Apo-1 activates nuclear factor κ B and induces interleukin-6 production. J. Inflamm. 45:161.
27. Ponton, A., M. Clement, and I. Stamenkovic. 1996. The CD95 (APO-1/Fas) receptor activates NF-κB independently of its cytotoxic function. J. Biol. Chem. 271:8991.
28. Abreu Martin, M. T., A. Vidrich, D. H. Lynch, and S. R. Targan. 1995. Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-α and ligation of Fas antigen. J. Immunol. 155:4147.
29. Ming, W., L. Bersani, and A. Mantovani. 1987 Tumor necrosis factor is chemotactic for monocytes and polymorphonuclear leukocytes. J. Immunol. 138:1469.
30. Figari, I., N. Mori, and J. Palladino MA. 1987. Regulation of neutrophil migration and superoxide production by recombinant tumor necrosis factor-α and β: comparison to recombinant interferon-γ and interleukin-1α. Blood 70:979.
31. Sayers, T., T. Wiltrout, C. A. Bull, A. C. Denn, 3rd, A. M. Pilaro, and B. Lokesh. 1988. Effect of cytokines on polymorphonuclear neutrophil infiltration in the mouse: prostaglandin- and leukotriene-independent induction of infiltration by IL-1 and tumor necrosis factor. J. Immunol. 141:1670.
32. Nozawa, K., N. Kayagaki, Y. Tokano, H. Yagita, K. Okumura, and H. Hasimoto. 1997. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum. 40:1126.
33. Tanaka, M., T. Suda, K. Haze, N. Nakamura, K. Sato, F. Kimura, K. Motoyoshi, M. Mizuki, S. Tagawa, S. Ohga, et al. 1996. Fas ligand in human serum. Nature Med. 2:317.
34. Hasegawa, D., S. Kojima, E. Tatsumi, A. Hayakawa, Y. Kosaka, H. Nakamura, M. Sako, Y. Osugi, S. Nagata, and K. Sano. 1998. Elevation of the serum Fas ligand in patients with hemophagocytic syndrome and Diamond-Blackfan anemia. Blood 91:2793
35. Toyozaki, T., M. Hiroe, M. Tanaka, S. Nagata, H. Ohwada, and F. Marumo. 1998. Levels of soluble Fas ligand in myocarditis. Am. J. Cardiol. 82:246.
36. Taieb, J., P. Mathurin, T. Poynard, M. Gougerot-Pocidalo, and S. Chollet-Martin. 1998. Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease. Lancet 351:1930.
37. Hashimoto, H., M. Tanaka, T. Suda, T. Tomita, K. Hayashida, E. Takeuchi, M. Kaneko, H. Takano, S. Nagata, and T. Ochi. 1998. Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 41:657.